Pimavanserin | 706779-91-1

Pimavanserin Properties

Melting point	100-103oC
Boiling point	604.2±55.0 °C(Predicted)
Density	1.15±0.1 g/cm3(Predicted)
storage temp.	Refrigerator
solubility	Methanol (Slightly)
pka	13.52±0.46(Predicted)
form	Solid
color	Pale Yellow to Pale Orange
InChI	InChI=1S/C25H34FN3O2/c1-19(2)18-31-24-10-6-20(7-11-24)16-27-25(30)29(23-12-14-28(3)15-13-23)17-21-4-8-22(26)9-5-21/h4-11,19,23H,12-18H2,1-3H3,(H,27,30)
InChIKey	RKEWSXXUOLRFBX-UHFFFAOYSA-N
SMILES	N(CC1=CC=C(F)C=C1)(C1CCN(C)CC1)C(NCC1=CC=C(OCC(C)C)C=C1)=O
CAS DataBase Reference	706779-91-1(CAS DataBase Reference)
FDA UNII	JZ963P0DIK
ATC code	N05AX17
UNSPSC Code	41116107
NACRES	NA.24

SAFETY

Risk and Safety Statements

Symbol(GHS)

GHS07

Signal word

Warning

Hazard statements

H315-H319-H335

Precautionary statements

P261-P264-P271-P280-P302+P352-P304+P340-P305+P351+P338-P312-P321-P362+P364-P332+P313-P337+P313-P403+P233-P405-P501

Hazard Codes

Xi

Safety Statements

24/25

WGK Germany

WGK 2

HS Code

29339900

Storage Class

3 - Flammable liquids

Hazard Classifications

Acute Tox. 4 Dermal
Acute Tox. 4 Inhalation
Acute Tox. 4 Oral
Eye Irrit. 2
Flam. Liq. 2

NFPA 704

	0
2		0

Pimavanserin price More Price(49)

Manufacturer	Product number	Product description	CAS number	Packaging	Price	Updated	Buy
Cayman Chemical	23462	Pimavanserin ≥98%	706779-91-1	5mg	$25	2026-04-30	Buy
Cayman Chemical	23462	Pimavanserin ≥98%	706779-91-1	10mg	$46	2026-04-30	Buy
Cayman Chemical	23462	Pimavanserin ≥98%	706779-91-1	25mg	$95	2026-04-30	Buy
Cayman Chemical	23462	Pimavanserin ≥98%	706779-91-1	50mg	$119	2026-04-30	Buy
Biosynth	FP27045	Pimavanserin	706779-91-1	0.1g	$150	2026-06-04	Buy

Product number	Packaging	Price	Buy
23462	5mg	$25	Buy
23462	10mg	$46	Buy
23462	25mg	$95	Buy
23462	50mg	$119	Buy
FP27045	0.1g	$150	Buy

Pimavanserin Chemical Properties, Uses, Production

Description

Pimavanserin is a kind of novel oral administrated drug for treatment of Parkinson's psychosis developed by Acadia pharmaceutical Company (US) with the trade name being Pimavanserin. In September 3rd 2014, it has been granted by the US Food and Drug Administration (FDA) for breakthrough therapy certification. Breakthrough therapy certification is created by the FDA for accelerating the development and review of new drugs for treatment of serious or life-threatening diseases.
Currently there are about seven millions to ten million of patients of Parkinson's disease worldwide with China contributing 2.6 million, ranking first in the world with 100,000 new patients emerging every year. More than 50% of patients of Parkinson's disease have had psychiatric symptoms (PDP). These psychiatric symptoms are mainly manifested as hallucinations and delusions, bringing greater challenge to the treatment and care for patients of Parkinson's disease. Dopamine is the primary target for the treatment of Parkinson's disease because most antipsychotics drugs will block the dopamine in the brain of the patients of Parkinson’s disease, making their situation of motor dysfunction be even worse, and thus currently not being suitable for these patients.
structure of Pimavanserin

Chemical Properties

Yellow Solid

Uses

Drug used in the treatment of Parkinson’s disease and psychosis.

Definition

ChEBI: Pimavanserin is a member of the class of ureas in which three of the four hydrogens are replaced by 4-fluorobenzyl, 1-methylpiperidin-4-yl, and 4-(isopropyloxy)benzyl groups. An atypical antipsychotic that is used (in the form of its tartrate salt) for treatment of hallucinations and delusions associated with Parkinson's disease. It has a role as an antipsychotic agent, a 5-hydroxytryptamine 2A receptor inverse agonist and a serotonergic antagonist. It is a member of ureas, a member of piperidines, a member of monofluorobenzenes, an aromatic ether and a tertiary amino compound. It is a conjugate base of a pimavanserin(1+).

General Description

Pimavanserin(706779-91-1) is a novel first-line drug of antipsychotic symptoms belongs to non-dopaminergic neurotransmitters with the drug targets being serotonin 2A receptor (5-HT2A), which can selectively block the 5-HT 2A receptor without affecting the action of dopamine with the routine administration being treatment via oral administration once daily. There are evidences showing that the drug is quite effective in the treatment of Parkinson's disease psychosis with well tolerance. Moreover, it does not block the dopamine receptors, and therefore does not lead to worsening of symptoms of Parkinson's disease. A 6-week-lasting randomized, double-blind, placebo-controlled trial has included 199 patients and evaluated the safety and efficacy of pimavanserin.

Biological Activity

Pimavanserin is an inverse agonist of the serotonin (5-HT) receptor subtype 5-HT_2A (IC₅₀ = 1.86 nM; K_i = 0.5 nM). It is selective for 5-HT_2A over a panel of 65 ion channels, enzymes, and receptors (K_is = >100 nM). Pimavanserin reduces head-twitch behavior and prepulse inhibition deficits induced by the 5-HT_2A receptor agonist DOI in rats at doses of 3 mg/kg, p.o. and 1-10 mg/kg, s.c., respectively. It also exhibits antipsychotic-like activity, reducing hyperactivity induced by (+)-MK-801 in mice. Pimavanserin acts synergistically with haloperidol or risperidone to suppress (+)-MK-801-induced hyperactivity and attenuates haloperidol- and risperidone-induced catalepsy in rats. Formulations containing pimavanserin have been used for the treatment of psychosis in Parkinson''s disease.

Side effects

Pimavanserin is a medication used to treat hallucinations and delusions associated with Parkinson's disease psychosis. Like all medications, it carries the risk of side effects. Common side effects of pimavanserin may include:
Bloating or swelling of the face, arms, hands, lower legs, or feet
confusion
nausea
rapid weight gain
unusual weight gain or loss
www.mayoclinic.org

Enzyme inhibitor

This orally active atypical non-dopaminergic antipsychotic[ (FWfree-base = 427.56 g/mol; CAS 706779-91-1 (free base) and 706782-28-7 (tartrate salt)), also known as ACP-103, Nuplazid and N-(4-fluorophenylmethyl)- N-(1-methyl-piperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenyl-methyl)carbamide, is a potent inverse agonist and antagonist at serotonin 5-HT2A receptors (Ki = 0.087 nM) and less so at serotonin 5-HT2C receptors (Ki = 0.44 nM). Pimavanserin shows low binding to σ1 receptors (Ki = 120 nM), with no appreciable affinity (Ki > 300 nM) to serotonin 5-HT2B, dopaminergic (including D2), muscarinic, histaminergic, or adrenergic receptors, or to calcium channels. 5-HT2A receptor dysregulation is implicated in both the etiology and treatment of schizophrenia, and the same receptor plays an active role in the regulation of sleep architecture. Nuplazid is specifically indicated in its FDA approval (April, 2016) for the treatment of hallucinations and delusions associated with Parkinson disease. Significantly, 5-HT2A serotonin receptor antagonists differentially regulate 5-HT2A receptor protein level in vivo. See also Ketanserin; RH-34; Risperidone; Ritanserin; Setoperone; Volinanserin.

storage

Store at -20°C

Mode of action

The mechanism of action of pimavanserin in the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis is unknown. However, the effect of pimavanserin could be mediated through a combination of inverse agonist and antagonist activity at serotonin 5-HT2A receptors and to a lesser extent at serotonin 5-HT2C receptors.
www.accessdata.fda.gov

References

[1] KIMBERLY E VANOVER. Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N’-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist.[J]. Journal of Pharmacology and Experimental Therapeutics, 2006, 317 2: 910-918. DOI: 10.1124/jpet.105.097006
[2] LUIS R GARDELL. ACP-103, a 5-hydroxytryptamine 2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models.[J]. ACS Applied Electronic Materials, 2007: 862-870. DOI: 10.1124/jpet.107.121715
[3] MCNAMARA P. Psychosis and Dementia in Parkinson’s Disease[C]. 2011: 0. DOI: 10.7551/mitpress/9780262016087.003.0011

Pimavanserin Preparation Products And Raw materials

Raw materials

Preparation Products

Pimavanserin Suppliers

Global Suppliers ( 246)

Supplier	Tel	Email	Country	ProdList	Advantage
Shanghai Yuke Chemicals Co., Ltd	13818767334	samwjf@163.com	China	159	58
Shanghai Boyle Chemical Co., Ltd.		sales@boylechem.com	China	2915	55
J & K SCIENTIFIC LTD.	18210857532 18210857532	jkinfo@jkchemical.com	China	96815	76
Chembest Research Laboratories Limited	021-20908456	sales@BioChemBest.com	China	5996	61
Adamas Reagent, Ltd.	400-6009262 15618770481	yhx@titansci.com	China	14098	59
LGM Pharma	1-(800)-881-8210	inquiries@lgmpharma.com	United States	2110	70
Shanghai Hanhong Scientific Co.,Ltd.	021-54306202 13764082696	info@hanhongsci.com	China	42917	64
Chemsky（shanghai）International Co.,Ltd.	021-50135380	shchemsky@sina.com	China	32273	50
China DongFan Chemical Co.,LTD	86-0571-85151182		China	5681	66
Dalian Meilun Biotech Co., Ltd.	0411-62910999 13889544652	sales@meilune.com	China	4765	58

Supplier	Advantage
Shanghai Yuke Chemicals Co., Ltd	58
Shanghai Boyle Chemical Co., Ltd.	55
J & K SCIENTIFIC LTD.	76
Chembest Research Laboratories Limited	61
Adamas Reagent, Ltd.	59
LGM Pharma	70
Shanghai Hanhong Scientific Co.,Ltd.	64
Chemsky（shanghai）International Co.,Ltd.	50
China DongFan Chemical Co.,LTD	66
Dalian Meilun Biotech Co., Ltd.	58

View Latest Price from Pimavanserin manufacturers

Update time	Product	Price	Min. Order	Purity	Supply Ability	Manufacturer
2026-09-14	Pimavanserin 706779-91-1	$350.00-650.00	1Kg/Bag	99% up, High Density	20 tons	Sinoway Industrial co., ltd.
2026-09-02	Pimavanserin 706779-91-1	$35.00	1kg	99%		Henan Fengda Chemical Co., Ltd
2026-08-20	Pimavanserin 706779-91-1	$1.10	1g	99.0% Min	100 Tons	Dideu Industries Group Limited

Pimavanserin
706779-91-1
$350.00-650.00
99% up, High Density
Sinoway Industrial co., ltd.

Pimavanserin
706779-91-1
$35.00
99%
Henan Fengda Chemical Co., Ltd

Pimavanserin
706779-91-1
$1.10
99.0% Min
Dideu Industries Group Limited

Pimavanserin Spectrum

Pimavanserin(706779-91-1)¹HNMR

706779-91-1 (Pimavanserin) Related Search:

Dimethylbenzylcarbinyl acetate Benzyl chloromethyl ether Benzyltrimethylammonium hydroxide Benzyldimethylcarbinyl butyrate TEMPO

1,1,3,3-Tetramethylurea Urea formaldehyde 2,2,6,6-Tetramethyl-4-piperidinol Unii-na83F1sjsr Pimavanserin

Bis(4-fluorobenzyl)aMine 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)urea Bis(4-fluorobenzyl)aMine 1,3-bis(4-isobutoxybenzyl)urea Liraglutide

Pimavanserin Phenylacetone Granular urea

1of4

Pimavanserin PIMAVANSERIN/1-(4-FLUOROBENZYL)-3-(4-ISOBUTOXYBENZYL)-1-(1-METHYLPIPERIDIN-4-YL)UREA Unii-jz963p0dik Pimavamserin N-(4-Fluorobenzyl)-N-(1-Methylpiperidin-4-yl)-N'-[[4-(2-Methylpropyloxy)phenyl]Methyl]carbaMide N-[(4-Fluorophenyl)Methyl]-N-(1-Methyl-4-piperidinyl)-N'-[[4-(2-Methylpropoxy)phenyl]Methyl]urea Urea,N-[(4-fluorophenyl)Methyl]-N-(1-Methyl-4-piperidinyl)-N'-[[4-(2-Methylpropoxy)phenyl]Methyl]- 1-(4-Fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1-methylpiperidin-4-yl)urea Pimavanserin(ACP-103) Pimvanserin Pimavanserin IMP Pimavanserin impurty Pimaserin ACP-103; ACP103; ACP 103 1-[(4-fluorophenyl)methyl]-1-(1-methyl-4-piperidinyl)-3-[[4-(2-methylpropoxy)phenyl]methyl]urea Pimavanserin Impurity Pimavanserin ISO 9001：2015 REACH Pimavanserin free base Pimanavserin Pimavanserin, 10 mM in DMSO Pimavanserin solution 1-(4-Fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1-methyl-4-piperidyl)urea D4-Pimavanserin Pimofanerol 1-[(4-fluorophenyl)Methyl]-1-(1-Methylpiperidin-4-yl)-3-{[4-(2-Methylpropoxy)phenyl]Methyl}urea Pimavanserin-d4 706779-91-1 4734/9/2 C25H34FN3O2 Intermediates & Fine Chemicals Pharmaceuticals Inhibitors MX